Millie
your market intelligence analyst
Search Results
152 results
Your search is now limited to «Celgene» expert search.
pharmaphorum 08/19/2019 08:04
Celgene has scored a major regulatory win ahead of its proposed merger with Bristol-Myers Squibb, with the FDA backing its rare bone marrow cancer drug Inrebic.
More from pharmaphorum:
Pharmafile 08/19/2019 06:35
Celgene is celebrating the approval in the US of its Janus kinase (JAK) 2 inhibitor Inrebic (fedratinib) in the treatment of intermediate-2 or high-risk primary or secondary myelofibrosis, a rare disorder of the bone ...
More from Pharmafile:
Celgene chief medical officer Dr Jay Backstrom said: “The approval of INREBIC is another important milestone for Celgene and underscores our commitment to people living with blood cancers.
More from Pharmaceutical Business Review:
Motley Fool 08/18/2019 09:00
And on Friday, Celgene announced that the FDA approved Inrebic (fedratinib) in treating myelofibrosis.
More from Motley Fool:
Reuters.com 08/16/2019 13:37
FDA approves Celgene's bone marrow cancer treatment.
More from Reuters.com:
Investing News Network 08/16/2019 12:35
Celgene (NASDAQ:CELG) has announced that the US Food and Drug Administration (FDA) has approved INREBIC to treat adult patients with myelofibrosis. As quoted in the press release: “The approval of INREBIC is another important milestone for Celgene and underscores our commitment to people living with blood cancers,” said Jay Backstrom, M.D., M.P.H., Chief Medical Officer …. .
BioPharma Dive 08/16/2019 11:50
While Celgene's top-selling blood cancer drug Revlimid (lenalidomide) was a key draw for Bristol-Myers, the pharma also made a case to skeptical investors that Celgene's experimental drugs could give it a foundation for the future.
More from BioPharma Dive:
FiercePharmaManufacturing 08/16/2019 11:30
The once-daily oral drug is the first new treatment in nearly a decade approved to treat the disease, Celgene said.
More from FiercePharmaManufacturing:
Human medicines European public assessment report (EPAR): Azacitidine Celgene, azacitidine, Myelodysplastic Syndromes,Leukemia, Myelomonocytic, Chronic,Leukemia, Myeloid, Acute, Date of authorisation: 02/08/2019, Status: Authorised.
More from European Medicines Agency - EMEA (EU):
IPWatchdog 08/11/2019 12:15
In the Celgene case, the panel actively discouraged safety by making it far easier to find virtually any safety-related invention obvious.
More from IPWatchdog:
Seeking Alpha 08/08/2019 14:07
As the Celgene (CELG) acquisition heads towards closure, investors need to position themselves for owning shares in the new Bristol-Myers Squibb (BMY.
More from Seeking Alpha:
Investor's Business Daily 08/08/2019 08:00
Pharmaceutical company Bristol-Myers Squibb (BMY) kicked off 2019 by announcing a $74 billion plan to buy biotech giant Celgene (CELG.
More from Investor's Business Daily:
MedCity News 07/30/2019 16:24
Celgene filing plans potentially mean two more CAR-Ts on the market by end of next year.
More from MedCity News:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications